Compositions and methods for cellular ageing, stress resilience, autophagy, inflammation and longevity
Compositions and methods are presented that that help reduce cellular ageing, improve cellular stress resilience, and/or promote increased longevity. Especially preferred compositions include a combination of a purine alkaloid, an isothiocyanate or thioglucoside, and a metal-containing antioxidant, where the purine alkaloid, the isothiocyanate or thioglucoside, and the metal-containing antioxidant may be chemically isolated compounds or extracts or other preparations from naturally occurring entities such as plants, bacteria, yeast, etc. Advantageously, contemplated compositions will be effective to reduce and repair oxidative stress, improve mitochondrial function, augment DNA repair and telomere maintenance, increase fatty acid metabolism, and modulate histone deacetylation.
1 . A method of increasing telomere length in a cell of a mammal via SIRT1 and SIRT6 upregulation, comprising:
administering an effective amount of a cytoprotective composition to the mammal so as to upregulate SIRT1 and SIRT6 to thereby increase telomere stability and length in the cell of the mammal;
wherein the cytoprotective composition includes a cytoprotective formulation comprising a combination of (a) a purine alkaloid, (b) an isothiocyanate or thioglucoside, (c) a metal-containing antioxidant; and
wherein the cytoprotective formulation is formulated for oral administration with a nutritionally or pharmaceutically acceptable carrier.
2 . A method of increasing global SIRT 1-7 activity in a mammal, comprising:
administering an effective amount of a cytoprotective composition to the mammal so as to increase global SIRT 1-7 activity in the mammal;
wherein the cytoprotective composition includes a cytoprotective formulation comprising a combination of (a) a purine alkaloid, (b) an isothiocyanate or thioglucoside, (c) a metal-containing antioxidant; and
wherein the cytoprotective formulation is formulated for oral administration with a nutritionally or pharmaceutically acceptable carrier.
3 . A method of increasing at least one of the level of NAD+ or the ratio of NAD+/NADH via upregulation of PGC-1α, in a mammal, comprising:
administering an effective amount of a cytoprotective composition to the mammal so as to upregulate PGC-1α to thereby increase at least one of the level of NAD+ or the ratio of NAD+/NADH, in the mammal;
wherein the cytoprotective composition includes a cytoprotective formulation comprising a combination of (a) a purine alkaloid, (b) an isothiocyanate or thioglucoside, (c) a metal-containing antioxidant; and
wherein the cytoprotective formulation is formulated for oral administration with a nutritionally or pharmaceutically acceptable carrier.
4 . The method of claim 3 , wherein the step of administering the effective amount of the cytoprotective composition is performed so as to increase the level of NAD+ in the mammal.
5 . The method of claim 3 , wherein the step of administering the effective amount of the cytoprotective composition is performed so as to increase the ratio of NAD+/NADH in the mammal.
6 . The method of claim 3 , wherein the cytoprotective composition further comprises one or more additional ingredients including selenium, a polyphenol, olive leaf extract, tributyrin, and/or BHB.